Dissemination of bla(KPC-2) in an NTEKPC by an IncX5 plasmid

Autor(es)

de Souza, Rosineide Cardoso ^[1] ; Gebieluca Dabul, Andrei Nicoli ^[2] ; dos Santos Boralli, Camila Maria ^[2] ; Zuvanov, Luiza ^[2] ; Baratella da Cunha Camargo, Ilana Lopes ^[2]

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Carlos, Genet & Evolut Dept, BR-13565905 Sao Carlos, SP - Brazil

^[2] Univ Sao Paulo, Sao Carlos Inst Phys, BR-13563120 Sao Carlos, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: PLASMID; v. 106, NOV 2019.
• Citações Web of Science: 0

Resumo

bla(KPC-2) is disseminated worldwide usually in Tn4401, a Tn3-family transposon, and primarily in Kiebsiella pneumoniae ST258, a well-known lineage that is distributed worldwide and responsible for several outbreaks. Although occurring rarely, bla(KPC-2) has been described in non-Tn4401 elements (NTEKPC), first in China and then in a few other countries. This study reports the dissemination of a bla(KPC-2)-carrying NTEKPC among ST11/CG258 K. pneumoniae strains and ST1642 K. quasipneumoniae subsp. quasipneumoniae AMKP9 in an Amazonian hospital. The dissemination was due to pAMKP10, an similar to 48 kbp IncX5 plasmid carrying Delta ISKpn6/bla(KPC-2)/ISKpn27 in a Tn1722-based unit. Although similar to NTEKPC-Ia from pICP048 described in China, a different transposase is present upstream of ISKpn27. Additionally, mutations were identified downstream of ISKpn27 but did not affect the bla(KPC-2) promoter regions. pAMKP10 conjugated in vitro only from CG258 isolates. Since CG258 strains are generally well adapted to the hospital environment, it is significant that pAMKP10 has found its way into this clinically significant clonal group. The impact of inter- and intraspecies dissemination of NTEKPCs and IncX5 plasmids harboring carbapenem resistance genes is unknown, but monitoring these plasmids could reveal their dissemination preferences. (AU)

• Processo FAPESP: 13/24952-0 - Padrões da emergência de enterococci e staphylococci multiresistentes no Brasil e busca por novos fármacos
• Beneficiário: Andrei Nicoli Gebieluca Dabul Dias de Sousa
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado